Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.
If you were prescribed this medicine, other products containing Ciclesonide may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.
for 2. What you need to know before you use Ciclesonide Advanz Pharma 3. How to use Ciclesonide Advanz Pharma 4. Possible side effects 5. How to store Ciclesonide Advanz Pharma 6. Contents of the pack and other information 1.
What Ciclesonide Advanz Pharma is what it is used for
What Ciclesonide Advanz Pharma is: Ciclesonide Advanz Pharma contains the active substance ciclesonide. Ciclesonide Advanz Pharma is a clear and colourless aerosol spray for you to breathe in through your mouth and into your lungs. It is a Preventer medication (corticosteroid) that has to be taken every day and which becomes active only after it has been inhaled into your lungs. What Ciclesonide Advanz Pharma is used for: Ciclesonide Advanz Pharma is used to treat persistent asthma in adult and adolescent patients (12 years old and more). How Ciclesonide Advanz Pharma works: Ciclesonide Advanz Pharma helps you to breathe more easily by decreasing the symptoms of your asthma and by lessening the chances of an asthma attack. The effect builds up over a period of time, so this medicine needs to be taken every day, even when you are feeling well. This medicine is not suitable for use in an acute attack of breathlessness. For quick relief from such an attack, use only your Reliever inhaler. 2.
e Ciclesonide Advanz Pharma
Do not use Ciclesonide Advanz Pharma
–
if you are allergic to ciclesonide or any of the other ingredients of this medicine. (listed in section 6).
Warnings and precautions Talk to your doctor, pharmacist or nurse before using Ciclesonide Advanz Pharma.
–
Before beginning treatment with this medicine, please tell your doctor if: you have ever been treated, or are currently being treated, for pulmonary tuberculosis (TB), fungal, viral or bacterial infections.
Check with your doctor if you are not sure. It is important to make sure that Ciclesonide Advanz Pharma is the right medicine for you. During your treatment with Ciclesonide Advanz Pharma contact your doctor immediately if: –
–
breathing becomes difficult and your symptoms, coughing, breathlessness, wheezing, tightness in the chest, increasing noises (rhonchi) or other symptoms of narrowing of the airways are getting worse. you experience blurred vision or other visual disturbances.
You should use your Reliever inhaler which will normally lead quickly to an improvement. –
you are waking up at night with your symptoms. you are not getting relief from using your Reliever inhaler.
Your doctor will decide on your further treatment. Specific patient groups Patients with severe asthma are at risk of acute asthma attacks. For such patients the doctor will carry out regular thorough asthma control checks, including a lung function test. Patients who are already taking corticosteroid tablets Ciclesonide Advanz Pharma can be used to replace your tablets, or to reduce the number of tablets you need to take. Please follow your doctor's instructions carefully. –
This will start about a week after you begin your Ciclesonide Advanz Pharma inhalations. The number of tablets you take will be reduced with caution over a period of time. During this period you may sometimes suffer from a general feeling of being unwell. In spite of this, it is important to continue both with your Ciclesonide Advanz Pharma inhalations and with slowly reducing the number of tablets you take. If you get serious symptoms such as nausea (feeling sick), vomiting (being sick), diarrhoea or a high temperature, contact your doctor. This process may sometimes reveal minor allergies such as rhinitis (inflammation of the inside of the nose) or eczema (itchy, reddening skin). If you have changed over from tablets, you will continue for a time to be at risk of reduced adrenal function, which is related to the corticosteroid tablets you take.
The symptoms of reduced adrenal function (e.g. dizziness, fainting, nausea, loss of appetite, moodiness, decrease in body hair, inability to cope with stress, weakness, headaches, memory problems, allergies, food cravings, and blood sugar disorders) may also continue for some time. –
You may also need to see a specialist to determine the extent of the reduction in adrenal function. Your doctor will also do regular checks on your adrenal function. During periods of stress, for example, having an operation, worsening asthma attacks, it is possible that you will need extra corticosteroid tablets. If so, you must carry a steroid warning card which says so.
Patients with liver or kidney disorders There is no need to adjust the dose of ciclesonide if you have liver or kidney problems. If you suffer from a severe liver condition, your doctor will check you more carefully for possible side effects resulting from disturbance of normal steroid production. Children This medicine is not recommended for children below the age of 12 because of a lack of information about its possible effects. Other medicines and Ciclesonide Advanz Pharma Tell your doctor or pharmacist if you are using, have recently taken/used or might use any other medicines, including medicines obtained without a prescription. Please inform your doctor before using Ciclesonide Advanz Pharma, if you are currently being treated for any fungal or viral infections with medicine containing:
Because there is not enough information about the effects of Ciclesonide Advanz Pharma on pregnant women, your doctor will discuss with you the risks and benefits of using Ciclesonide Advanz Pharma.
–
–
Ciclesonide (the active ingredient in Ciclesonide Advanz Pharma) may be taken during pregnancy only when the possible benefits to the mother justify the possible risk to the developing baby. If your doctor decides that you can continue using Ciclesonide Advanz Pharma, the smallest possible dose of ciclesonide will be used to maintain asthma control. The adrenal function will be carefully monitored in children of mothers who received corticosteroids during pregnancy. Talk to your doctor if you want to use Ciclesonide Advanz Pharma during breast-feeding. It is not known whether inhaled ciclesonide passes into the breast milk in humans. Prescribing Ciclesonide Advanz Pharma to women who are breast feeding will therefore only be considered if the expected benefit to the mother outweighs the possible risk to the child.
Driving and using machines Ciclesonide Advanz Pharma and its ingredients have no or negligible effects on the ability to drive or to use machines. Ciclesonide Advanz Pharma contains ethanol This medicine contains 4.7 mg of alcohol (ethanol) in each actuation. The amount in a dose of this medicine is equivalent to less than 1 ml beer or wine. The small amount of alcohol in this medicine will not have any noticeable effects. 3.
Ciclesonide Advanz Pharma
Always use this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure. –
If you have just started to use this medicine instead of, or as well as, taking corticosteroid tablets, see section 2, Patients who are already taking corticosteroid tablets. How much Ciclesonide Advanz Pharma should I take each day? Your doctor will have spoken to you about how much of your medicine you need to take each day. This will depend on your individual need.
–
The recommended dose of Ciclesonide Advanz Pharma is 160 micrograms once daily, which leads to asthma control in the majority of patients. In some patients a dose reduction to 80 micrograms, once daily, may be an adequate dose for maintaining effective control of their asthma. An increased dosage of Ciclesonide Advanz Pharma may become necessary for a short period of time in patients who suffer a severe worsening of their asthma symptoms. This can be up to 640 micrograms per day, delivered as 320 micrograms twice daily but no data confirming the additional therapeutic effect after 3 months with these higher doses are available.
–
If necessary, your doctor may also prescribe corticosteroid tablets and/or, in the case of an infection, an antibiotic. –
Your doctor will adjust your dose to the minimum necessary to control your asthma. You should start to notice an improvement in your symptoms (wheezing, tight chest and coughing) within 24 hours.
When should I use my Ciclesonide Advanz Pharma? In most cases, either in the morning or in the evening – as one or two puffs once a day. Follow your doctor's instructions very carefully. It is important that you take Ciclesonide Advanz Pharma regularly every day, even if you feel better. If you find that you have to use your Reliever inhaler more than 2‐3 times a week, you should contact your doctor to have your medicine reviewed. How do I use my Ciclesonide Advanz Pharma? It is important that a doctor, nurse or pharmacist shows you first how to use your Ciclesonide Advanz Pharma inhaler properly. A good technique will make sure you are receiving the correct amount into your lungs. Please use the instructions in this leaflet as a reminder. You may wish to practise in front of the mirror for the first couple of times until you are confident that you are using your Ciclesonide Advanz Pharma inhaler properly. Make sure that none of your medicine is escaping from the top or sides of your mouth. If you have a new inhaler, or if you have not used your inhaler for a week or more, it must be tested before you use it. Remove the mouthpiece cover and press down three times on the canister inside the inhaler to release three puffs into the air – away from you. You do not need to shake your Ciclesonide Advanz Pharma before using it. The medicine is already in a very fine solution, mixed to ensure you receive the correct dose with each puff. During inhalation, you can either be sitting down or standing up. Follow these instructions carefully and use the pictures to guide you.
1.
Remove the mouthpiece cover and check the mouthpiece, both the inside and the outside, to make sure that it is both clean and dry.
2.
Hold the inhaler upside down (base of the canister at the top) with your forefinger on the base of the canister and your thumb under the mouthpiece.
3.
Breathe out as far as is comfortable. Do not breathe out through the inhaler.
4.
Place the mouthpiece in your mouth and close your lips firmly around it.
5.
Just after starting to breathe in through your mouth, press down with your forefinger on the top of the inhaler to release a puff of the medicine while you are still breathing in slowly and deeply. Please take care that the puff of medicine does not escape through the top, bottom or sides of your mouth.
6.
Hold your breath, take the inhaler from your mouth and remove your finger from the top of the inhaler. Continue holding your breath for about ten seconds or as long as is comfortable. Breathe out slowly through your mouth. Do not breathe out through the inhaler.
It is important that you do not rush steps 3 to 6.
7.
If you have been instructed to take another puff, wait about half a minute and repeat steps 3 to 6.
8.
After use, always replace the mouthpiece cover to keep out dust. Replace firmly and snap into position.
For hygiene reasons Please clean the mouthpiece weekly with a dry tissue, both inside and out. 1. 2. 3.
remove the mouthpiece cover, do not remove the inhaler from the plastic actuator; using a dry, folded tissue, wipe over the front of the small hole where the medicine comes out. do not use water or any other liquids.
A correct technique will ensure the right amount of Ciclesonide Advanz Pharma is getting into your lungs every time you use your inhaler. Your doctor will check your inhalation technique regularly to ensure that your treatment can have the very best effect. When the canister is completely empty you will not feel or hear any of the propellant being discharged.
If you begin to feel wheezy or tightness in the chest after using your Ciclesonide Advanz Pharma : –
Do not take any more puffs. Use your reliever inhaler to help your breathing. Contact your doctor immediately. If you find it difficult to use the inhaler, your doctor may recommend the use of a spacer. The spacer that fits the Ciclesonide Advanz Pharma is called AeroChamber Plus Flow-Vu spacer device. If you use the AeroChamber Plus Flow-Vu spacer device, please follow the instructions provided with it. Your doctor or pharmacist will be able to advise you about the device. If you use more Ciclesonide Advanz Pharma than you should It is important that you take your dose as advised by your doctor. You should not increase or decrease your dose without seeking medical advice. There is no specific treatment necessary if you have used too much Ciclesonide Advanz Pharma but you should inform your doctor. If high doses are used over long periods, a certain degree of reduction in adrenal function cannot be ruled out and control of the adrenal function may be necessary. If you forget to use Ciclesonide Advanz Pharma If you have forgotten to use your Ciclesonide Advanz Pharma, just take your usual dose when it is next due. Do not take a double dose to make up for a forgotten dose. If you stop using Ciclesonide Advanz Pharma Even if you feel better, you should not stop using your Ciclesonide Advanz Pharma. If you do stop using this medicine, you must tell your doctor immediately. If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse. 4.
Like all medicines, this medicine can cause side effects, although not everybody gets them. If you notice any of the following serious side effects, stop using this medicine and talk to your doctor straight away: –
Severe allergic reactions such as swelling of lips, tongue and throat (may affect up to 1 in 1 000 people) Allergic reactions: skin rashes, redness, itching or weals like nettle rash and hives (may affect up to 1 in 100 people) Cough, or wheezing, which gets worse soon after taking an inhalation (may affect up to 1 in 100 people)
The other side effects seen with Ciclesonide Advanz Pharma are usually mild. In most cases you can continue with your treatment. The side effects you may experience are:
–
Uncommon side effects (may affect up to 1 in 100 people): Hoarseness Burning, inflammation, irritation of mouth or throat Oral thrush (oral fungal infection) Headache Blurred vision Bad taste Dryness of mouth or throat Nausea or vomiting
–
Rare side effects (may affect up to 1 in 1 000 people): Sensation of heartbeat (palpitations) Discomfort or pain in the abdomen High blood pressure
–
Frequency not known, but may also occur: Sleeping problems, depression or feeling worried, restless, nervous, over-excited or irritable. These effects are more likely to occur in children Eye disease causing visual disturbance (central serous chorioretinopathy) Ciclesonide Advanz Pharma may affect the normal production of corticosteroids in your body. This is usually seen in patients taking high doses over a long period of time. These effects may include: –
Reduced rate of growth in adolescents A thinning of the bones Possible clouding of the lens of the eye (cataracts) causing blurred vision Loss of vision caused by abnormally high pressure in the eye (glaucoma) Moon-shaped face, weight gain in the upper body and thinning arms and legs (Cushingoid features or Cushing syndrome).
Adolescents who are receiving treatment for a long period of time should have their height checked regularly by their doctor. If your growth rate is slowed, your doctor will adjust your treatment if possible to the lowest dose at which effective control of asthma is maintained. Corticosteroid tablets can lead to more side effects than a corticosteroid inhaler such as Ciclesonide Advanz Pharma. If you have been taking steroid tablets before or during the use of Ciclesonide Advanz Pharma, the risk of side effects from the tablets may continue for a period of time. Regular check-ups with your doctor will ensure that you are taking the right dose of Ciclesonide Advanz Pharma for you. Regular check-ups will also identify any side effects early on and reduce the chances of them worsening.
Please remember: If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist. Reporting of side effects If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via Yellow Card Scheme Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects you can help provide more information on the safety of this medicine. 5.
Ciclesonide Advanz Pharma
Keep this medicine out of the sight and reach of children. Do not use this medicine after the expiry date which is stated on the label and the carton after EXP. The expiry date refers to the last day of that month. The container contains a pressurised liquid. Do not expose to temperatures above 50°C. The container should not be punctured, broken or burned even if it seems empty. As with most inhaled medicines in pressurised containers, the healing effect of this medicinal product may become smaller when the container is cold. However, Ciclesonide Advanz Pharma delivers the same level of dose from minus 10°C to plus 40°C. If the inhaler gets very cold, take the inhaler out of the plastic case and warm it in your hands for few minutes before use. Never use anything else to warm it up. Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment. 6.
What Ciclesonide Advanz Pharma contains –
The active ingredient is ciclesonide. Each actuation releases a puff (dose delivered through the mouthpiece) that contains either 80 or 160 micrograms of ciclesonide. The other ingredients are anhydrous ethanol and propellant (Norflurane). This medicine contains fluorinated greenhouse gases. Each inhaler contains 0.0088 kg of HFA-134a (Norflurane) corresponding to 0.0126 tonne CO2 equivalent (global warming potential GWP= 1430).
What Ciclesonide Advanz Pharma looks like and contents of the pack Ciclesonide Advanz Pharma consists of a clear and colourless liquid in a pressurised aluminium container, which delivers through a mouthpiece an accurately measured dose of ciclesonide in the form of a spray. The canister is fitted into a plastic casing incorporating a mouthpiece and fitted with a green (Ciclesonide Advanz Pharma 80 micrograms) or purple (Ciclesonide Advanz Pharma 160 micrograms) dust cap. Pack sizes: 1 Inhaler with 120 metered actuations Marketing Authorisation Holder Advanz Pharma Limited Unit 17 Northwood House Northwood Crescent Dublin 9 D09 V504 Ireland +44 (0)208 588 9131 [email protected] Manufacturer Genetic S.p.A Contrada Canfora 84084 Fisciano (SA) Italy
This leaflet was last revised in 12/2024.
Ciclesonide Advanz Pharma 80 mcg per metered dose pressurised inhalation, solution comes as inhaler containing 80mcg. Always follow the dose your doctor or pharmacist has given you, and read the leaflet that comes with the medicine.
The active substance in Ciclesonide Advanz Pharma 80 mcg per metered dose pressurised inhalation, solution is ciclesonide.
Medicines with the same active substance, strength and form include: Alvesco 80 mcg Inhaler. They are interchangeable only if your prescriber or pharmacist says so.
This leaflet reproduces the patient information leaflet approved for Ciclesonide Advanz Pharma 80 mcg per metered dose pressurised inhalation, solution, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.
Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.
The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.
Ciclesonide Advanz Pharma is indicated in treatment to control persistent asthma in
adults and adolescents (12 years and older).
The medicinal product is for inhalation use only.
Posology
Dosing recommendation for adults and adolescents:
The recommended dose of Ciclesonide Advanz Pharma is 160 micrograms once daily, which leads to asthma control in the majority of patients. In patients with severe asthma and while reducing or discontinuing oral corticosteroids a higher dose of up to 640 mcg/day may be used (see section 5.1). Patients should be given a dose of inhaled ciclesonide which is appropriate to the severity of their disease.
Symptoms start to improve with Ciclesonide Advanz Pharma within 24 hours of treatment. Once control is achieved, the dose of Ciclesonide Advanz Pharma should be individualised and titrated to the minimum dose needed to maintain good asthma control.
Dose reduction to 80 micrograms once daily may be an effective maintenance dose for some patients.
Ciclesonide Advanz Pharma should preferably be administered in the evening although morning dosing of Ciclesonide Advanz Pharma has also been shown to be effective. The final decision on evening or morning dosing should be left to the discretion of the physician.
Patients with severe asthma are at risk of acute attacks and should have regular assessments of their asthma control including pulmonary function tests. Increasing use of short-acting bronchodilators to relieve asthma symptoms indicates deterioration of asthma control. If patients find that short-acting relief bronchodilator treatment becomes less effective, or they need more inhalations than usual, medical attention must be sought. In this situation, patients should be reassessed and consideration given to the need for increased anti-inflammatory treatment therapy (e.g. a higher dose of Ciclesonide Advanz Pharma for a short period (see section 5.1) or a course of oral corticosteroids). Severe asthma exacerbations should be managed the usual way.
To address specific patient needs, such as finding it difficult to press the inhaler and breathe in at the same time, Ciclesonide Advanz Pharma can be used with the AeroChamber Plus Flow-Vu spacer device.
Special populations
Elderly and patients with renal or hepatic impairment
There is no need to adjust the dose in elderly patients or those with hepatic or renal impairment.
Paediatric population
The safety and efficacy of ciclesonide in children aged under 12 years have not yet been established. No sufficient data are available.
Method of administration
Precautions to be taken before handling or administering the medicinal product
The patient needs to be instructed how to use the inhaler correctly.
If the inhaler is new or has not been used for one week or more, three puffs should be released into the air. No shaking is necessary as this is a solution aerosol.
During inhalation, the patient should preferably sit or stand, and the inhaler should be held upright with the thumb on the base, below the mouthpiece.
Instruct the patient to remove the mouthpiece cover, place the inhaler into their mouth, close their lips around the mouthpiece, and breathe in slowly and deeply. While breathing in through the mouth, the top of the inhaler should be pressed down. Then, patients should remove the inhaler from their mouth, and hold their breath for about 10 seconds, or as long as is comfortable. The patient is not to breathe out into the inhaler. Finally, patients should breathe out slowly and replace the mouthpiece cover.
The mouthpiece should be cleaned with a dry tissue or cloth weekly. The inhaler should not be washed or put in water.
For instructions on use of medicinal product before administration, see section 6.6.
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
As with all inhaled corticosteroids, Ciclesonide Advanz Pharma should be administered with caution in patients with active or quiescent pulmonary tuberculosis, fungal, viral or bacterial infections, and only if these patients are adequately treated.
As with all inhaled corticosteroids, Ciclesonide Advanz Pharma is not indicated in the treatment of status asthmaticus or other acute episodes of asthma where intensive measures are required.
As with all inhaled corticosteroids, Ciclesonide Advanz Pharma is not designed to relieve acute asthma symptoms for which an inhaled short-acting bronchodilator is required.
Patients should be advised to have such rescue medication available.
Systemic effects of inhaled corticosteroids may occur, particularly at high doses prescribed for prolonged periods. These effects are much less likely to occur than with oral corticosteroids. Possible systemic effects include: Cushing's syndrome, Cushingoid features, adrenal suppression, growth retardation in children and adolescents, decrease in bone mineral density, cataract and glaucoma, and more rarely, a range of psychological or behavioural effects including psychomotor hyperactivity, sleep disorders, anxiety, depression or aggression (particularly in children). It is therefore important that the dose of inhaled corticosteroid is titrated to the lowest dose at which effective control of asthma is maintained.
Visual disturbance
Visual disturbance may be reported with systemic and topical corticosteroid use. If a patient presents with symptoms such as blurred vision or other visual disturbances, the patient should be considered for referral to an ophthalmologist for evaluation of possible causes which may include cataract, glaucoma or rare diseases such as central serous chorioretinopathy (CSCR) which have been reported after use of systemic and topical corticosteroids.
Paediatric population
It is recommended that the height of children and adolescents receiving prolonged treatment with inhaled corticosteroids is regularly monitored. If growth is slowed, therapy should be reviewed with the aim of reducing the dose of inhaled corticosteroid, if possible to the lowest dose at which effective control of asthma is maintained. In addition, consideration should be given to referring the patient to a paediatric respiratory specialist.
Hepatic impairment
There is no data available in patients with severe hepatic impairment. An increased exposure in patients with severe hepatic impairment is expected and these patients should therefore be monitored for potential systemic effects.
Adrenal impairment
The benefits of inhaled ciclesonide should minimise the need for oral steroids. However, patients transferred from oral steroids remain at risk of impaired adrenal reserve for a considerable time after transferring to inhaled ciclesonide. The possibility of respective symptoms may persist for some time. These patients may require specialised advice to determine the extent of adrenal impairment before elective procedures. The possibility of residual impaired adrenal response should always be considered in an emergency (medical or surgical) and elective situations likely to produce stress, and appropriate corticosteroid treatment considered.
For the transfer of patients being treated with oral corticosteroids:
The transfer of oral steroid-dependent patients to inhaled ciclesonide, and their subsequent management, needs special care as recovery from impaired adrenocortical function, caused by prolonged systemic steroid therapy, may take a considerable time.
Patients who have been treated with systemic steroids for long periods of time, or at a high dose, may have adrenocortical suppression. With these patients adrenocortical function should be monitored regularly and their dose of systemic steroid reduced cautiously.
After approximately a week, gradual withdrawal of the systemic steroid is started by reducing the dose by 1 mg prednisolone per week, or its equivalent. For maintenance doses of prednisolone in excess of 10 mg daily, it may be appropriate to cautiously use larger reductions in dose at weekly intervals.
Some patients feel unwell in a non-specific way during the withdrawal phase despite maintenance or even improvement of respiratory function. They should be encouraged to persevere with inhaled ciclesonide and to continue withdrawal of systemic steroid, unless there are objective signs of adrenal insufficiency.
Patients transferred from oral steroids whose adrenocortical function is still impaired should carry a steroid warning card indicating that they need supplementary systemic steroid during periods of stress, e.g. worsening asthma attacks, chest infections, major intercurrent illness, surgery, trauma, etc.
Replacement of systemic steroid treatment with inhaled therapy sometimes unmasks allergies such as allergic rhinitis or eczema previously controlled by systemic drug.
Paradoxical bronchospasm with an immediate increase of wheezing or other symptoms of bronchoconstriction after dosing should be treated with an inhaled short-acting bronchodilator, which usually results in quick relief. The patient should be assessed and therapy with Ciclesonide Advanz Pharma should only be continued, if after careful consideration the expected benefit is greater than the possible risk. Correlation between severity of asthma and general susceptibility for acute bronchial reactions should be kept in mind (see section 4.8).
Patients inhaler technique should be checked regularly to make sure that inhaler actuation is synchronised with inhaling to ensure optimum delivery to the lungs.
Concomitant treatment with ketoconazole or other potent CYP3A4 inhibitors, including cobicistat-containing products, is expected to increase the risk of systemic side-effects. The combination should be avoided unless the benefit outweighs the increased risk of systemic side effects of corticosteroids (see section 4.5), in which case patients should be monitored for systemic corticosteroid side-effects.
This medicine contains 4.7 mg of alcohol (ethanol) in each dose. The amount in a dose of this medicine is equivalent to less than 1 ml beer or wine. The small amount of alcohol in this medicine will not have any noticeable effects.
In vitro data indicate that CYP3A4 is the major enzyme involved in the metabolism of the active metabolite of ciclesonide M1 in man. In a drug-drug interaction study at steady state with ciclesonide and ketoconazole as a potent CYP3A4 inhibitor, the exposure to the active metabolite M1 increased approximately 3.5-fold, whereas the exposure to ciclesonide was not affected. Therefore the concomitant administration of potent inhibitors of CYP 3A4 (e.g. ketoconazole, itraconazole cobicistat-containing products and ritonavir or nelfinavir) should be avoided unless the benefit outweighs the increased risk of systemic side effects of corticosteroids, in which case patients should be monitored for systemic corticosteroid side-effects
Fertility and Pregnancy
There are no adequate and well-controlled studies in pregnant women.
In animal studies glucocorticoids have been shown to induce malformations (see section 5.3). This is not likely to be relevant for humans given recommended inhalation doses.
As with other glucocorticoids, ciclesonide should only be used during pregnancy if the potential benefit to the mother justifies the potential risk to the fetus. The lowest effective dose of ciclesonide needed to maintain adequate asthma control should be used.
Infants born of mothers who received corticosteroids during pregnancy are to be observed carefully for hypoadrenalism.
Breast-feeding
It is unknown whether inhaled ciclesonide is excreted in human breast milk. Administration of ciclesonide to women who are breast-feeding should only be considered if the expected benefit to the mother is greater than any possible risk to the child.
Ciclesonide Advanz Pharma has no or negligible influence on the ability to drive and use machines.
Approximately 5% of patients experienced adverse reactions in clinical trials with Ciclesonide Advanz Pharma given in the dose range 40 to 1280 micrograms per day. In the majority of cases, these were mild and did not require discontinuation of treatment with Ciclesonide Advanz Pharma.
Frequency
Uncommon
(>1/1 000, <1/100)
Rare
(1/10 000 – 1/ 1 000)
Not known
(cannot be estimated from the available data)
System Organ Class
Cardiac Disorders
Palpitations**
Gastrointestinal Disorders
Nausea, vomiting*
Bad taste
Abdominal pain*
Dyspepsia*
General disorders and administration site conditions
Application site reactions
Application site dryness
Immune System Disorders
Angioedema
Hypersensitivity
Infections and infestations
Oral fungal infections*
Nervous System Disorders
Headache*
Eye Disorders
Blurred vision (see also section 4.4)
Central Serous Chorioretinopathy
Psychiatric Disorders
Psychomotor hyperactivity, sleep disorders, anxiety, depression, aggression, behavioural changes (predominantly in children)
Respiratory, thoracic and mediastinal disorders
Dysphonia Cough after inhalation*
Paradoxical bronchospasm*
Skin and subcutaneous tissue disorders
Eczema and rash
Vascular disorders
Hypertension
* Similar or lower incidence when compared with placebo
** Palpitations were observed in clinical trials in cases mostly confounded with concomitant medication with known cardiac effects (e.g. theophylline or salbutamol).
Paradoxical bronchospasm may occur immediately after dosing and is an unspecific acute reaction to all inhaled medicinal products, which may be related to the active substance, the excipient, or evaporation cooling in the case of metered dose inhalers. In severe cases, withdrawal of Ciclesonide Advanz Pharma should be considered.
Systemic effects of inhaled corticosteroids may occur, particularly at high doses prescribed for prolonged periods. Possible systemic effects include Cushing's syndrome, Cushingoid features, adrenal suppression, growth retardation in children and adolescents, decrease in bone mineral density, cataract, glaucoma (see also section 4.4).
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme, Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
Acute:
Inhalation by healthy volunteers of a single dose of 2880 micrograms of ciclesonide was well tolerated. The potential for acute toxic effects following overdose of inhaled ciclesonide is low. After acute overdosage no specific treatment is necessary.
Chronic:
After prolonged administration of 1280 micrograms of ciclesonide, no clinical signs of adrenal suppression were observed. However, if higher than recommended dosage is continued over prolonged periods, some degree of adrenal suppression cannot be excluded. Monitoring of adrenal reserve may be necessary.
Ask anything about Ciclesonide Advanz Pharma 80 mcg per metered dose pressurised inhalation, solution. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.
Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.
We use essential cookies to make the site work. We would also like to set optional cookies to understand how the site is used, so we can improve it. We will not set optional cookies unless you accept. See our cookie policy and privacy policy.